

RECEIVED
CENTRAL FAX CENTER

AUG 11 2006

USSN 09/554,533
Atty Docket No. 238/086USIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BEELY, Nigel R.A., et al.

Appln. No.: 09/554,533

371 Filing Date: 11 July 2002

For: *Novel Exendin Agonist Compounds*

Art Unit: 1642

Examiner: LIU, Samuel W.

Atty. Docket: 238/086 US

Confirm. No.: 1938

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:


FACSIMILE TRANSMITTAL COVER SHEETCertificate of Transmission Under 37 C.F.R. 1.8

The following documents are being submitted via facsimile transmittal in response to the Office Action, mailed July 12, 2006:

<u>Documents(s)</u>	<u>No. of Pages</u>
Applicant's Comment on Interview Summary	1
<i>Facsimile Cover Sheet</i>	<i>1</i>
Total Pages	2

Should any other fee become due or credit become payable during the pendency of these proceedings, the Commissioner is authorized to charge or credit the same to Deposit Account Number 010535.

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number to telephone number (571) 273-8300 on this 11th of August, 2006.


Kelly B. Solomon

RECEIVED
CENTRAL FAX CENTER

AUG 11 2006

USSN 09/554,533
Atty Docket No. 238/086US

In re Application of:

BEELY, Nigel R.A., et al.

Appln. No.: 09/554,533

371 Filing Date: 11 July 2002

For: *Novel Exendin Agonist Compounds*

Art Unit: 1653

Examiner: LIU, Samuel W.

Atty. Docket: 238/086 US

Confirm. No.: 1938

Applicant's Comment on Interview Summary

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450


Sir:

In response to the Interview Summary mailed 12 July 2006, Applicants respectfully submit the following summary of the substance of the interview.

Applicants wish to thank the Examiner for his time and guidance during the telephonic interview conducted with Applicant's representatives, David Marsh and James Butler on July 5, 2006. During this interview, the parties discussed the restriction groups and claims. Applicants elected Group II claims, reserving the right to traverse the restriction requirement.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: 11-Aug-06

By: 
Susan J. Myers Fitch
Registration No. 55,477

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936